During the last session, Helius Medical Technologies Inc (NASDAQ:HSDT)’s traded shares were 49437.0, with the beta value of the company hitting 1.14. The 52-week high for the HSDT share is $5.33, that puts it down -1803.57 from that peak though still a striking 3.57% gain since the share price plummeted to a 52-week low of $0.27. The company’s market capitalization is $1.69M, and the average intraday trading volume over the past 10 days was 60530.0 shares, and the average trade volume was 2.02 million shares over the past three months.
Helius Medical Technologies Inc (HSDT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. HSDT has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.92.
Helius Medical Technologies Inc (NASDAQ:HSDT) trade information
Helius Medical Technologies Inc (HSDT) registered a -1.79% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.79% in intraday trading to $0.28, hitting a weekly high. The stock’s 5-day price performance is -15.04%, and it has moved by -31.93% in 30 days. Based on these gigs, the overall price performance for the year is -94.83%. The short interest in Helius Medical Technologies Inc (NASDAQ:HSDT) is 16608.0 shares and it means that shorts have 0.13 day(s) to cover.
Helius Medical Technologies Inc (HSDT) estimates and forecasts
In the rating firms’ projections, revenue will decrease -1.92% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 100k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 110k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 135k and 182k respectively. In this case, analysts expect current quarter sales to shrink by -25.93% and then drop by -39.56% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 63.29%. While earnings are projected to return 85.22% in 2025.
HSDT Dividends
Helius Medical Technologies Inc is due to release its next quarterly earnings on 2025-Mar-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Helius Medical Technologies Inc (NASDAQ:HSDT)’s Major holders
Helius Medical Technologies Inc insiders own 0.32% of total outstanding shares while institutional holders control 4.04%, with the float percentage being 4.05%.
